Shopping Cart
- Remove All
- Your shopping cart is currently empty
Piclozotan (anhydrous), a 5-HT1A receptor agonist, demonstrated significant neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model, ameliorating motor complications in patients with advanced Parkinson's disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.444 € | 6-8 weeks | |
50 mg | 1.881 € | 6-8 weeks | |
100 mg | 2.375 € | 6-8 weeks |
Description | Piclozotan (anhydrous), a 5-HT1A receptor agonist, demonstrated significant neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model, ameliorating motor complications in patients with advanced Parkinson's disease. |
In vivo | Piclozotan (SUN N4057) (0.018 and 0.036 mg/kg/h; continuous subcutaneous infusion; 3 to 4 weeks; Parkinsonian rats) significantly lengthened the duration of rotational behavior by 26% and attenuated the increase in striatal levodopa-derived extracellular dopamine levels compared with the control group. Piclozotan (0.018 and 0.036 mg/kg/h, plasma concentrations 5.3±0.7 and 14.3±2.9 ng/ml) reduced levodopa-induced forelimb hyperkinesia by 55% and 69%, respectively, at 1h relative to the control.[1] |
Alias | SUNN-4057, SUN-N-4057, SUNN4057, SUN-4057, SUN4057 |
Molecular Weight | 409.91 |
Formula | C23H24ClN3O2 |
Cas No. | 182415-09-4 |
Smiles | O=C1C=2C(OC=C(Cl)N1CCCCN3CCC(=CC3)C4=CC=CC=N4)=CC=CC2 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.